|
|
Volumn 292, Issue 5517, 2001, Pages 614-615
|
|
Drug patients: Universities, NIH hear the price isn't right on essential drugs
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABACAVIR;
STAVUDINE;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ESSENTIAL DRUG;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
DRUG COST;
DRUG INDUSTRY;
ECONOMIC ASPECT;
FINANCIAL MANAGEMENT;
LAW;
NOTE;
PATENT;
PRIORITY JOURNAL;
SOUTH AFRICA;
ARTICLE;
DEVELOPING COUNTRY;
ECONOMICS;
HEALTH CARE ORGANIZATION;
HUMAN;
UNITED STATES;
UNIVERSITY;
ANTI-HIV AGENTS;
DEVELOPING COUNTRIES;
DRUG COSTS;
DRUG INDUSTRY;
DRUGS, ESSENTIAL;
HUMANS;
NATIONAL INSTITUTES OF HEALTH (U.S.);
PATENTS;
RESEARCH SUPPORT;
UNITED STATES;
UNIVERSITIES;
|
|
EID: 0035957504
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.292.5517.614 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|